Contineum Therapeutics Q2 Adj $(0.39) Misses $(0.35) Estimate
Portfolio Pulse from Benzinga Newsdesk
Contineum Therapeutics (NASDAQ:CTNM) reported a Q2 adjusted loss of $(0.39) per share, missing the analyst consensus estimate of $(0.35) by 11.43%. This represents a 146.43% decrease from the earnings of $0.84 per share in the same period last year.
August 13, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Contineum Therapeutics reported a Q2 adjusted loss of $(0.39) per share, missing the analyst consensus estimate of $(0.35) by 11.43%. This significant miss and the 146.43% decrease from last year's earnings of $0.84 per share are likely to negatively impact the stock price in the short term.
The significant miss on earnings estimates and the drastic year-over-year decrease in earnings per share are likely to lead to a negative market reaction. Investors typically react unfavorably to such earnings misses, especially when the decline is as steep as 146.43%.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100